Skip to main content

Table 1 Baseline Characteristics

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

   N=99
Sex Male 77 (78%)
Female 22 (23%)
Age   73.2
BCVA (logMAR)   0.49 (0.43)
Medical history Diabetes 20 (20%)
Hypertension 49 (50%)
Disease duration (years)   0.5 (±0.92)
Type of AMD typical AMD 83 (84%)
PCV 13 (13%)
RAP 3 (3%)
FA classification Predominantly classic 24 (24%)
Minimally classic 17 (17%)
Occult 58 (59%)
Past history None 97 (98%)
Photocoagulation 1 (1%)
PDT 0 (0%)
Other anti-VEGF drugs 0 (0%)
Others 1 (1%)
  1. AMD age-related macular degeneration, BCVA best corrected visual acuity, logMAR logarithm of the minimal angle of resolution, PCV polypoidal choroidal vasculopathy, RAP retinal angiomatous proliferation, VEGF vascular endothelial growth factor
\